MAPT and Alzheimer disease: Particularly, tau protein phosphorylated at a threonine residue at position 181 (p-Tau 181) plasma levels are 3.5-fold increased in patients with AD as compared to controls, and this change is greater than the one of any other plasma biomarker [17].